Haemostatix

Haemostatix looking forward to a healthy future.

”The Company believes it is leading the world in the development of this product – once on the market HaemoPlax should start earning the company some seriously huge figures."

Sarah Middleton, Chief Executive, Haemostatix Ltd

A difficult problem becomes a major opportunity

Haemostatix was formed when Sarah Middleton, an experienced biotech product developer, and Alison Goodall, Professor of Thrombosis and Haemostasis at Leicester University, identified a problem with platelet transfusions.

Whenever patients have to undergo the procedure they may stand the risk of being infected by Hepatitis, HIV or even CJD, the human form of Mad Cow Disease. On top of that, the platelets have a very short shelf life and so are very costly.

What they came up with is a highly innovative solution: a synthetic alternative which mimics the role played by platelets. It is sterile and, because it is synthetic, has an extremely long shelf life. In one go they solved the two problems – and now have a potentially highly lucrative product.

A life-saving innovation

Innovations do not come more significant than those which have the potential to save lives. HaemoPlax is now at the testing stage which, although time consuming and costly, is the only major obstacle remaining before the product is released onto the market.

The concept for Haemoplax first saw the light of day back in 1990, but after a lot of hard work from Sarah, the idea was shelved when the company she was working for was taken over. She never let go of the dream though and resuscitated it in 2003 when she launched Haemostatix. A spin out company from the University of Leicester, it is supported by emda through the Lachesis Fund and the Regional Venture Capital Fund.

More than just a good idea

The impact of this innovation has been widely felt not just throughout the biotech industry but in the East Midlands too. What started as just a twinkle in Sarah Middleton's eye all those years ago has now grown into an operation that is set to become a truly huge regional biotech company.

But most importantly thanks to hard work, dedication, and more than anything innovative thinking, the new product is set to be a safer, more cost effective replacement for platelet transfusion

Looking ahead

With patents pending, Haemostatix has exclusive rights to HaemoPlax’s full financial potential, so the company's future is totally secure. All from one innovative idea.

Click for Haemostatix website.